Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels ; volume:18 ; number:1 ; day:3 ; month:12 ; year:2018 ; pages:1-3 ; date:12.2018
BMC cancer ; 18, Heft 1 (3.12.2018), 1-3, 12.2018
- Urheber
-
Groenland, Stefanie L.
Katz, Daniela
Huitema, Alwin D. R.
Steeghs, Neeltje
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-5043-9
- URN
-
urn:nbn:de:101:1-2019011921140693177476
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Groenland, Stefanie L.
- Katz, Daniela
- Huitema, Alwin D. R.
- Steeghs, Neeltje
- SpringerLink (Online service)
Ähnliche Objekte (12)
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Pazopanib in advanced soft tissue sarcomas
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Pazopanib in advanced soft tissue sarcomas
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Pazopanib in advanced soft tissue sarcomas
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis